[Neopterin as a marker of aspecific immunostimulation with Propionibacterium avidum KP-40 in patients with gastrointestinal tumors. A prospective randomized study].
This prospective randomized study demonstrated that a preoperative intravenous infusion of 10 mg of the bacterial preparation Propionibacterium avidum KP-40 to patients with gastrointestinal tumors significantly (P less than 0.001) enhanced the secretion of neopterin, measurable as long-lasting (greater than 16 days) elevated urine excretion. Postoperative re-infusion of P. avidum KP-40 caused (statistically significant (p less than 0.001] re-enhancement of neopterin urine levels.
Peters
K M
KM
Orthopädische Klinik der Medizinischen Fakultät der RWTH Aachen.
Bornhofen
B
B
Grundmann
R
R
Ko
H L
HL
Beuth
J
J
Waters
W
W
Pichlmaier
H
H
Pulverer
G
G
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D001708:Biopterins / Q000031:analogs & derivatives* / Q000652:urine; D015179:Colorectal Neoplasms / Q000628:therapy*; D005260:Female; D006801:Humans; D007114:Immunization; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D019798:Neopterin; D011424:Propionibacterium; D011446:Prospective Studies; D011897:Random Allocation; D013274:Stomach Neoplasms / Q000628:therapy*
D014408:Biomarkers, Tumor; D001708:Biopterins; D019798:Neopterin
Neopterin als Marker einer unspezifischen Immunstimulation mittels Propionibacterium avidum KP-40 bei Patienten mit gastrointestinalen Tumoren. Eine prospektiv randomisierte Studie.